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Abstract
Initiation of ART during acute HIV-1 infection may prevent persistent immune activation. We
analyzed longitudinal CD38+HLA-DR+ CD8+ T cell percentages in 31 acutely infected
individuals who started early (median 43 days since infection) and successful ART, and
maintained viral suppression through 96 weeks. Pre-therapy a median of 72.6% CD8+ T cells
were CD38+HLA-DR+, and while this decreased to 15.6% by 96 weeks, it remained substantially
higher than seronegative controls (median 8.9%, p=0.008). Shorter time to suppression predicted
lower activation at 96 weeks. These results support the hypothesis that very early events in HIV-1
pathogenesis may result in prolonged immune dysfunction.
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INTRODUCTION
Interventions during acute HIV infection (AHI) may present a unique opportunity to alter
the pathogenesis of the disease. In the natural history of HIV infection, early and complex
virus-host interactions lead to chronic depletion and hyperactivation of T cells.1 Within
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weeks of HIV acquisition, the host innate immune system responds with a cytokine storm
that likely produces the symptoms of acute retroviral syndrome.1,2,3 CD4+ and CD8+ cells
become activated. But for rare individuals, host immune responses reduce but fail to fully
suppress viremia. During acute infection and in the absence of treatment, CD8+ cell
activation reaches a steady state.4 And while the mechanisms by which immune activation
contributes to immunodeficiency are not fully understood, an individual’s level of CD8+ cell
activation independently predicts the rate at which HIV disease progresses.5
Antiretroviral therapy (ART) reduces mortality in HIV-infected individuals through
virologic suppression (VS), reconstitution of CD4+ cells, and reduction of T cell activation.
Although ART reduces T cell activation, many persons with treated and suppressed chronic
HIV infection have persistently elevated levels of activation.6,7 Persistent activation may
slow the reconstitution of CD4+ cells and increase mortality both from AIDS and non-AIDS
events.6 While the phenomenon of persistent immune activation is primarily described
following chronic HIV infection (CHI), the activation outcomes of acutely infected and
treated individuals are not well described.
While effective,8 the personal health benefits of starting ART during AHI are unproven.9,10
A short course of ART started during AHI reduces the symptoms of acute retroviral
syndrome and may decrease the rate of CD4+ cell count decline after ART
discontinuation.11 In addition, ART provided during AHI may reduce the viral set point.12,13
While the possible benefits of providing a short course of ART during AHI have been
investigated, the impact of long term ART begun early after infection on immune activation
is unknown.
In this study, we analyzed longitudinal dynamics of CD8+ cell activation in acutely infected
adults treated with ART. We selected patients with the best possible treatment outcomes
(those who started immediate ART, achieved VS, and at 96 weeks remained suppressed) in
order to determine the efficacy of ART in preventing chronic persistent immune activation.
We compared CD8+ cell activation levels of AHI patients to seronegative controls, and
determined whether the timing of ART initiation or rapidity of VS were associated with
levels of activation in the setting of effectively treated HIV-1.
METHODS
Adults diagnosed with AHI and linked to care at University of North Carolina at Chapel Hill
(UNC), Duke University, or Emory University were enrolled in an open label, NNRTI- or
PI-based ART treatment trial within 45 days of AHI diagnosis. We defined AHI by a
negative or indeterminate enzyme immunoassay (EIA) or a negative HIV RNA test within
45 days of enrollment plus reproducibly detectable HIV RNA by amplification methods. All
participants had blood sent for baseline HIV genotyping prior to ART initiation. We
included only patients who achieved VS (HIV RNA ≤200 copies/mL) by 48 weeks and
sustained suppression through 96 weeks. Patients were excluded if CD8+ activation was not
measured pre-treatment and then serially through 96 weeks (±12 weeks).
At enrollment, acute retroviral syndrome (ARS) symptoms were recorded as previously
described.8,14 We estimated the date of HIV infection as 14 days prior to the onset of
symptoms consistent with ARS.3,15 The time (in days) from the estimated date of infection
to AHI diagnosis and to ART initiation was calculated. Sexually transmitted infections
(STIs) in the 8 weeks preceding HIV diagnosis were recorded.
Prior to ART and at weeks 12, 24, 48, 72, and 96 after therapy initiation, the HIV RNA level
and the percent of CD8+ cells expressing CD38 and HLA-DR were measured. HIV RNA
was quantified using the Roche Amplicor Monitor ultrasensitive assay or the Abbott
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RealTime HIV-1 assay. The percent CD38+ HLA-DR+ CD8+ cells was measured on fresh
blood samples collected in EDTA tubes. Activated CD8+ cells were identified using the
following antibodies: αCD3-PerCP, αCD8 FITC, αHLA-DR-APC, and αCD38-PE.
Antibody staining was evaluated using a 4-color Calibur flow cytometer instrument (Becton
Dickinson, San Jose, CA). In the same laboratory, thirty HIV-seronegative volunteers (70%
women and median age 32 years) provided fresh blood samples for measurement of CD8+
cell activation using the same methods. Beyond age and gender, the clinical characteristics
of seronegative volunteers were not available. We defined normal CD8+ activation as less
than or equal to the 95th percentile of the seronegative cohort’s distribution of activation
levels.
Pearson’s Chi-squared test was used for bivariable analyses between categorical baseline
characteristics and immune activation. The Wilcoxon rank-sum test was used to compare the
percent activation between acutely HIV infected and seronegative participants and for
continuous pre-therapy characteristics of the AHI cohort. We calculated the proportion of
AHI patients whose T cell activation normalized by 96 weeks. Using multivariable linear
regression with generalized estimating equations, we determined the impact of the timing of
ART initiation and the rapidity of VS on immune activation. SAS version 9.2 (Cary, NC)
and Stata 11 (College Station, TX) were used for analyses. The study was approved by the
UNC and Duke Institutional Review Boards. All participants provided written informed
consent.
RESULTS
Of 138 adults with AHI who initiated ART within 45 days of diagnosis since 1998, 31 met
the criteria for analysis. We excluded 14 AHI patients without sustained suppression for 96
weeks, 67 without CD8+ activation markers measured longitudinally, and 26 who had not
yet reached 96 weeks. Baseline demographic, virologic, and immunologic characteristics
were similar between those included and excluded from the analysis (data not shown).
Median age at therapy initiation was 32 years (range 19-64) and 29 patients (94%) were men
(Table 1). At diagnosis, 97% reported at least one (median 6) ARS-associated symptom.
One participant reported no symptoms of AHI and therefore, his estimated date of infection
was not determined. In the 8 weeks preceding AHI diagnosis, 3 (10%) participants had a
documented STI (genital herpes, chlamydia, or non-gonococcal urethritis).
At AHI diagnosis, 16 (52%) participants tested EIA negative, 9 (29%) tested EIA positive
but western blot (WB) negative or indeterminate, and 6 (20%) tested EIA and WB positive
with a negative or indeterminate test in the prior 30 days. Each patient had at least two pre-
ART viral loads. The median observed peak HIV RNA level was 5.86 log10 copies/ml (IQR
5.49-6.15). By the date of therapy initiation the median HIV RNA level had decreased to
5.27 log10 copies/ml (IQR 4.50-5.77). The median CD4+ cell count nadir was 392 cells/
mm3, and 5 (16%) participants had a nadir CD4+ cell count less than 200 cells/mm3.
The median time from acquisition to AHI diagnosis was 25 days (IQR 19-31) and from
acquisition to ART initiation was 43 days (IQR 39-53). In this cohort, 28 (90%) patients
received NNRTI-based regimens (co-formulated emtricitabine, tenofovir, and efavirenz or
co-formulated emtricitabine and tenofovir plus nevirapine), 1 patient received a PI-based
regimen (stavudine, didanosine, and nelfinavir), and for 2 participants the regimen type was
missing. We were not able to compare the effect of regimen type on immune activation.
Three patients (10%) had transmitted drug resistance (TDR), but only 1 patient required a
change of therapy. The median time to VS was 12 weeks (IQR 8-17).
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Pre-therapy, the median percent CD38+HLA-DR+ CD8+ cells was 72.6 (IQR 22.6-92.6).
CD8+ activation decreased substantially from baseline to week 12 and then more slowly
during subsequent measurements (Figure 1). From weeks 48 to 96, the median activation of
ART-treated AHI patients decreased by 3.8% (p=0.07). However, at 96 weeks, the median
percent CD38+HLA-DR+ CD8+ cells remained higher in participants with ART-treated
AHI versus the seronegative controls [15.6 (IQR 11.1-22.6) vs. 8.9 (IQR 5.8-14), p<0.01].
Approximately 40% of AHI patients failed to reach normal levels of activation by 96 weeks
(Figure 1).
In bivariable analyses, log10 peak viral load, pre-treatment CD8+ cell activation, and time to
VS were associated with CD8+ activation at 96 weeks (all p<0.05). Among both the AHI
patients and seronegative controls, we did not find an association between age or gender and
CD8+ activation. Recent STI diagnosis among AHI patients was also not associated with
higher levels of immune activation. In multivariable analyses, shorter time from estimated
date of infection to ART initiation was not associated with a reduction in CD8+ activation at
96 weeks (p=0.6). However, after adjustment for age, CD4+ cell nadir, and peak viral load,
shorter time to VS predicted a reduction of CD8+ activation at 96 weeks (p=0.002). For
every 1 month decrease in time to VS, CD8+ activation at 96 weeks decreased by 0.85%.
As part of a recently published study,16 four (13%) participants also underwent
measurements of the size of the viral reservoir (at mean 92 weeks of ART). There was a
positive but non-significant correlation between the log10-transformed frequency of latently
infected cells (reservoir size) and CD8+ activation at 96 weeks (Spearman’s rho=0.8,
p=0.2), as well as a correlation between frequency of latently infected cells and low-level
plasma viremia as measured by a single-copy assay.16
DISCUSSION
Among 31 acutely HIV infected patients with rapid linkage to care, early initiation of ART,
and rapid and durable VS, CD8+ activation decreased substantially during the first 12 weeks
of therapy and then decreased more slowly with increased duration of VS. Despite 2 years of
suppressive ART, AHI patients had a higher CD8+ activation compared with seronegative
controls, with 40% failing to reach normal levels. While not fully understood, immune
activation appears to play a central role in HIV pathogenesis,17 and this study builds on the
existing evidence in CHI that immune activation persists in many patients.6,7
Data from this study add to a discordant story regarding the immunologic benefits of starting
ART during acute/early infection.4 During one ART interruption trial, patients who started
ART during acute versus early HIV infection had no difference in activated CD8+ cells at
48 weeks.18 However, more recently patients who started ART earlier (median 75 days of
infection) had lower levels of CD8+ cell activation versus those who started later (median
3.1 years).19 We found no association between the timing of ART initiation and CD8+
activation, possibly due to the narrow range (21-67 days) of time to treatment within our
cohort. As our cohort consisted of patients with successful and durable VS, our results may
not be representative of all AHI patients. Further, as CD8+ activation levels may vary
depending on laboratory technique and whether fresh or previously frozen cells are used, our
results on fresh cells are not directly comparable to other cohorts of patients receiving ART.
Unfortunately, a direct comparison of CD8+ activation between acute and chronically
infected patients at our center, which would have strengthened our findings, was not
feasible.
One possible explanation for persistence of immune activation is the extensive and rapid
depletion of gut associated lymphoid tissue (GALT) which may result in a state of chronic
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hyperactivation and inadequate immune restoration.20,21 Persistently elevated levels of
activated lymphocytes were found in the GI tract 3-7 years after suppressive ART was
initiated during acute or early infection even while peripheral blood activation markers
normalized.22 In our study, while only 60% of patients by 96 weeks had reached a level
within the range of uninfected subjects, activation decreased with increased duration of VS
(Figure 1). This observation suggests that with time, further normalization of peripheral
blood activation markers may occur. However, peripheral blood lymphocytes represent only
a tiny fraction of all lymphocytes and GALT may be a better (but more logistically
challenging) site for examination of the overall immunological status of HIV infected
individuals.
While median levels of CD8+ activation remained higher than controls, we found that more
rapid VS predicted reduced immune activation. Despite the very high viral load seen during
AHI, the time to VS during ART may actually be shorter than seen with CHI.8 Time under
the viremia curve in the setting of AHI has been shown to correlate with the size of the viral
reservoir in resting CD4+ cells.16 A correlation between the frequency of latently infected
cells and low-level plasma viremia as measured by a single-copy assay was also reported.16
Release of virus from this reservoir may produce low level viremia and immune
activation.23 Therefore, limiting the reservoir size could reduce CD8+ activation. The
correlation we identified, in 4 patients, between reservoir size and immune activation did not
reach statistical significance. These preliminary observations deserve future study, and we
suggest that therapy that rapidly suppresses viremia should be further examined in the
setting of AHI.
The goal of this analysis was to investigate those individuals who had an optimal response to
ART, in effect to evaluate a “best-case” scenario. Therefore, our cohort may not be
representative of all AHI patients (due to our selection for durable VS). In addition, we had
limited knowledge regarding the health of seronegative controls. The control group
consisted of employees at a University hospital. Beyond age and gender, we unfortunately
had no additional information regarding their medical histories. Pro-inflammatory co-
infections (such as hepatitis B/C, CMV, and/or STIs) may have been less common among
controls and could have produced the difference in CD8+ activation seen between ART-
treated AHI patients and seronegative controls.
In the early stages of HIV infection, virus-host interactions result in steady states of HIV
RNA and CD8+ activation. These parameters determine the rate at which HIV progresses,
and may be associated with risk of death from non-AIDS-associated conditions.24 In this
study, we found that initiation of ART during acute HIV-1 infection failed to prevent the
persistence of immune activation at 96 weeks of suppressive therapy. These results suggest
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Initiation of ART during acute HIV-1 infection may prevent persistent immune
activation. We analyzed longitudinal CD38+HLA-DR+ CD8+ T cell percentages in 31
acutely infected individuals who started early (median 43 days since infection) and
successful ART, and maintained viral suppression through 96 weeks. Pre-therapy a
median of 72.6% CD8+ T cells were CD38+HLA-DR+, and while this decreased to
15.6% by 96 weeks, it remained substantially higher than seronegative controls (median
8.9%, p=0.008). Shorter time to suppression predicted lower activation at 96 weeks.
These results support the hypothesis that very early events in HIV-1 pathogenesis may
result in prolonged immune dysfunction.
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Figure 1. CD8+ cell activation in AHI patients during 96 weeks of ART
Dynamics of CD8+ cell activation among 31 ART-treated acutely HIV infected individuals
and comparison of 96 week activation levels to 30 seronegative controls.
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Table 1
Baseline demographic and disease characteristics of 31 acutely HIV-infected individuals at initiation of ART.
Characteristics
Number of participants 31
Age, median years (range) 32 (19-64)
Male sex, N (%) 29 (94)
Race/ethnicity, N (%)
 White/non-Hispanic 19 (61)
 African-American 12 (39)
Sexual risk group, N (%)
 MSM 24 (77)
 Heterosexual 7 (23)
Symptoms of ARS, median N (range) 6 (0-15)
Testing pattern at diagnosis, N (%)
 EIA neg/NAAT pos 16 (52)
 EIA pos/WB neg/ind 8 (26)
 EIA pos/WB pos with neg/ind test past 30 days 7 (22)
Nadir CD4+ cell count, median cells/mm3 (IQR) 392 (289-501)
Peak viral load, median log10copies/ml (IQR) 5.86 (5.49-6.15)
CD38+HLA-DR+CD8+ cells, median percent (IQR) 72.6 (22.6-92.6)
ARS-acute retroviral syndrome; EIA-enzyme immunoassay; NAAT-nucleic acid amplification test; WB-western blot
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